GeoVax Announces Publication Highlighting GEO-CM04S1 as Next-Generation COVID-19 Vaccine for Immunocompromised Patients

GeoVax Labs announced the publication of a peer-reviewed article in the European Society of Medicine's Medical Research Archives. The article highlights the clinical and immunologic rationale for GeoVax's next-generation COVID-19 vaccine candidate, GEO-CM04S1. Designed to address the limitations of first-generation COVID-19 vaccines in immunocompromised patients, GEO-CM04S1 is a dual-antigen vaccine delivered via a Modified Vaccinia Ankara (MVA) viral vector. The publication discusses the vaccine's scientific rationale, preclinical studies, and clinical findings supporting its development as a vaccine for immunocompromised individuals.